



## **THERMOGENESIS CORP. FILES SHELF REGISTRATION STATEMENT**

### **ON FORM S-3**

**(RANCHO CORDOVA, CA), January 6, 2011**—ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).

If and when declared effective by the SEC, the registration statement will enable ThermoGenesis to offer and sell differing amounts up to an aggregate of \$20 million of common stock or warrants, or any combination thereof, subject to applicable SEC rules and limitations. Although the registration statement relating to these securities has been filed with the SEC, it has not yet become effective and at the present time the Company has no specific plans to issue securities under the registration statement. The specifics of any future offerings, including the pricing, terms and use of proceeds of any such securities offered by ThermoGenesis, will be established at the time of the offerings and will be described in a prospectus supplement filed with the SEC at the time of each offering.

The registration statement is intended to provide ThermoGenesis the flexibility to access public capital markets in order to fund the company's strategic growth plans, working capital associated with integration of new products and potential marketing partnerships, and other general corporate purposes, including capital expenditures related to the Company's growth.

These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Thereafter, ThermoGenesis will provide specific terms of any offerings of securities in one or more supplements to this registration statement. This press release is not an offer to sell or a solicitation of any offer to buy, nor shall there be any sales of securities in any state or jurisdiction in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

## About ThermoGenesis Corp.

ThermoGenesis Corp. ([www.thermogenesis.com](http://www.thermogenesis.com)) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

- The BioArchive<sup>®</sup> System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP<sup>®</sup> AutoXpress<sup>™</sup> Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP<sup>™</sup> MarrowXpress<sup>™</sup> and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
- The Res-Q<sup>™</sup> 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
- The CryoSeal<sup>®</sup> FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: <http://www.thermogenesis.com>

Contact: Investor Relations

+1-916-858-5107, or

[ir@thermogenesis.com](mailto:ir@thermogenesis.com)